Dr. James Bortner is a Vice President of the Oncology Business Unit and has helped to develop the program since its inception at SAI MedPartners. He provides support for operational functions within oncology and executive oversight and management of projects.

Dr. Bortner has played an integral role in several oncology projects in solid tumors and hematological malignancies. His support and strategic insight has helped to advise pharmaceutical and biotech clientele on various clinical and commercial aspects of product development. Projects include supporting major companies in the exciting immunotherapy space, including checkpoint inhibitors and CAR-T cell therapy.

Dr. Bortner earned his PhD in biochemistry and molecular biology from the Pennsylvania State University College of Medicine and completed postdoctoral research at the University of Pennsylvania. He has over 10 years of experience in oncology, including benchside and translational clinical research. Dr. Bortner’s research has led to 10 publications, including invited reviews in highly reputable peer-reviewed journals.